References:
Arber D, Orazi A, Hasserjian R et al. The 2016 revision to the World Health Organization classification of myeloid
neoplasms and acute leukemia. Blood 2016;127(20):2391-405.
Bejar R, Papaemmanuil E, Haferlach T et al. Somatic Mutations in MDS Patients Are Associated with Clinical
Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International
Working Group for Prognosis in MDS-Molecular Committee. Blood 2015;126(23):907.
Bejar R, Stevenson K, Abdel-Wahab O et al. Clinical effect of point mutations in myelodysplastic syndromes. NEJM
2011;364(26):2496-506.
DiNardo C, Stein E, de Botton S et al. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory
AML. NEJM 2018;378(25):2386-2398.
Fenaux P, Platzbecker U, Mufti G et al. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
NEJM 2020;382(2):140-151.
Gotlib J, Kluin-Nelemans H, George T et al. Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.
NEJM 2016;374(26):2530-41.
Haferlach T, Nagata Y, Grossmann V et al. Landscape of genetic lesions in 944 patients with myelodysplastic
syndromes. Leukemia 2014;28(2):241-7.
Meggendorfer M, Roller A, Haferlach T et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia
(CMML). Blood 2012;120(5):3080-8.
Orazi A et al. Myelodysplastic Syndromes/Myeloproliferative Neoplasms, Chapter 5, in: Swerdlow S, Campo E,
Harris N et al (Eds.). World Health Organization Classification of Tumours of Haematopoietic and Lymphiod
Tissues, Revised 4th edition. Volume 2. IARC Press, Lyon, 2017, 88-96.
Papaemmanuil E, Gerstung M, Malcovati L et al. Clinical and biological implications of driver mutations in
myelodysplastic syndromes. Blood 2013;122(22):3616-27.
Stone R, Mandrekar S, Sanford B et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3
Mutation. NEJM 2017;377(5):454-464.
SCIENTIFIC PROGRAMME
SESSION I
ETIOLOGY OF MDS
SESSION II
BIOLOGY OF MDS –
GENETIC ABNORMALITIES
SESSION III
BIOLOGY OF MDS:
STEM CELLS AND THE
MICROENVIRONMENT
SESSION IV
DIAGNOSTIC WORKUP
AND PROGNOSTIC
FACTORS IN MDS
SESSION V
SPECIFIC SUBTYPES
OF MDS, BASED ON
MORPHOLOGY AND
MOLECULAR BIOLOGY
SESSION VI
TREATMENT OF MDS
SESSION VII
CURRENT PROGRESS IN
THE TREATMENT OF MDS
SESSION VIII
FUTURE TREATMENTS
AND TREATMENT
STRATEGIES IN MDS
SESSION IX
LATE-BREAKING TALKS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
AS E-POSTERS
DISCLOSURES